These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 15889966)

  • 1. Azimilide dihydrochloride.
    Carlson M
    Expert Rev Cardiovasc Ther; 2005 May; 3(3):387-91. PubMed ID: 15889966
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Azimilide dihydrochloride: a unique class III antiarrhythmic agent.
    Tran HT
    Heart Dis; 1999; 1(2):114-6. PubMed ID: 11720612
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Azimilide dihydrochloride, a novel antiarrhythmic agent.
    Karam R; Marcello S; Brooks RR; Corey AE; Moore A
    Am J Cardiol; 1998 Mar; 81(6A):40D-46D. PubMed ID: 9537222
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cumulative experience of azimilide-associated torsades de pointes ventricular tachycardia in the 19 clinical studies comprising the azimilide database.
    Pratt CM; Al-Khalidi HR; Brum JM; Holroyde MJ; Schwartz PJ; Marcello SR; Borggrefe M; Dorian P; Camm AJ;
    J Am Coll Cardiol; 2006 Aug; 48(3):471-7. PubMed ID: 16875971
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of isoproterenol on the class III effect of azimilide in humans.
    Dorian P; Dunnmon P; Elstun L; Newman D
    J Cardiovasc Pharmacol Ther; 2002 Oct; 7(4):211-7. PubMed ID: 12490966
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of azimilide and d,l-sotalol on the heart rate and blood pressure response to isoproterenol in anesthetized rats.
    Mittelstadt SW; Maynard AE; Benn DR; Lowe ER; Kostreva DR
    Cardiovasc Drugs Ther; 1997 Sep; 11(4):591-8. PubMed ID: 9358964
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Azimilide causes reverse rate-dependent block while reducing both components of delayed-rectifier current in canine ventricular myocytes.
    Gintant GA
    J Cardiovasc Pharmacol; 1998 Jun; 31(6):945-53. PubMed ID: 9641481
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The azimilide post-infarct survival evaluation (ALIVE) trial.
    Camm AJ; Karam R; Pratt CM
    Am J Cardiol; 1998 Mar; 81(6A):35D-39D. PubMed ID: 9537221
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Suppression of inducible ventricular arrhythmias by intravenous azimilide in dogs with previous myocardial infarction.
    Drexler AP; Micklas JM; Brooks RR
    J Cardiovasc Pharmacol; 1996 Dec; 28(6):848-55. PubMed ID: 8961084
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Azimilide.
    Clemett D; Markham A
    Drugs; 2000 Feb; 59(2):271-7; discussion 278-9. PubMed ID: 10730550
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the rate-dependent properties of the class III antiarrhythmic agents azimilide (NE-10064) and E-4031: considerations on the mechanism of reverse rate-dependent action potential prolongation.
    Groh WJ; Gibson KJ; Maylie JG
    J Cardiovasc Electrophysiol; 1997 May; 8(5):529-36. PubMed ID: 9160229
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Azimilide dihydrochloride: a new class III anti-arrhythmic agent.
    Abrol R; Page RL
    Expert Opin Investig Drugs; 2000 Nov; 9(11):2705-15. PubMed ID: 11060832
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of the novel antiarrhythmic agent azimilide on experimental atrial fibrillation and atrial electrophysiologic properties.
    Nattel S; Liu L; St-Georges D
    Cardiovasc Res; 1998 Mar; 37(3):627-35. PubMed ID: 9659446
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiarrhythmic efficacy of azimilide in patients with atrial fibrillation. Maintenance of sinus rhythm after conversion to sinus rhythm.
    Pritchett EL; Kowey P; Connolly S; Page RL; Kerr C; Wilkinson WE;
    Am Heart J; 2006 May; 151(5):1043-9. PubMed ID: 16644334
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New advances in class III antiarrhythmic drug therapy.
    Sager PT
    Curr Opin Cardiol; 1999 Jan; 14(1):15-23. PubMed ID: 9932203
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of the class III antiarrhythmic agent azimilide in rodent models of ventricular arrhythmia.
    Brooks RR; Carpenter JF; Miller KE; Maynard AE
    Proc Soc Exp Biol Med; 1996 May; 212(1):84-93. PubMed ID: 8618956
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Azimilide for atrial fibrillation: clinical trial results and implications.
    Pritchett EL; Marcello SR
    Card Electrophysiol Rev; 2003 Sep; 7(3):215-9. PubMed ID: 14739716
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The class III effect of azimilide is not associated with reverse use-dependence in open-chest dogs.
    Qi XQ; Newman D; Dorian P
    J Cardiovasc Pharmacol; 1999 Dec; 34(6):898-903. PubMed ID: 10598136
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiarrhythmic drugs: present and future.
    Sharma S
    J Assoc Physicians India; 2007 Apr; 55 Suppl():43-6. PubMed ID: 18368867
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of isoproterenol-induced tachycardia by azimilide in the isolated perfused guinea pig heart.
    Miller KE; Carpenter JF; Brooks RR
    Cardiovasc Drugs Ther; 1998 Mar; 12(1):83-91. PubMed ID: 9607136
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.